DSpace logo

Use este identificador para citar ou linkar para este item: http://repositorioinstitucional.uea.edu.br//handle/riuea/4125
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorSilva, Lucyane Mendes da-
dc.date.available2022-08-10-
dc.date.available2022-08-11T17:02:32Z-
dc.date.issued2019-08-03-
dc.identifier.urihttp://repositorioinstitucional.uea.edu.br//handle/riuea/4125-
dc.description.abstractThe incidence of fungal infections has increased worldwide, especially in the hospital setting, representing one of the major infectious complications in hospitalized patients and contributing to high morbidity and mortality. Particularly in patients with hematological diseases, who undergoing intensive chemotherapy therapy, or who deplete their immune system, leaving them susceptible to developing infections such as opportunistic drugs, neutropenia and other risk factors. The most common etiological agents responsible for infectious processes are Aspergillus spp. 38-80% and Candida spp. 28-58%, being related to resistance to antifungals widely used in therapy. Research at the genetic level contributes to a better understanding of the molecular epidemiology and evolutionary mechanisms of these pathogens. Thus, this study aimed to characterize the molecular level of fungal species that cause infectious processes of patients treated by the Amazon Hospital Hematology and Hemotherapy Foundation. This is a cross-sectional, prospective and descriptive study. The data collection period was from November 2017 to October 2018. The records were used through medical records, SoftLab system and iDoctor. Identification of yeast species and susceptibility testing (Fluconazole, Voriconazole, Caspofungin, Micafungin, Amphotericin B and Flucytosine) were performed with the automated Vitek-2 Compact equipment. The identification of filamentous fungal species was performed with the Internal Transcript Spacer gene. Also within the scope of molecular epidemiology, genotyping by the Multi Locus Sequence Typing method was performed to define the sequence types and common ancestors of the clinical species and phylogenetic tree. With the initial analysis of the results obtained, we found a total of 162 patients, 91 (56.2%) males and 71 (44%) females, with a mean age of 32 years; all of them of Brazilian nationality, being 150 (92.6%) born in the state of Amazonas; 66 (41%) did not study; 110 (68%) do not have occupation. Of the patients diagnosed with a haematological disease, acute lymphoblastic leukemia was the most frequent with 64 (39%) cases, followed by Acute Myeloid Leukemia with 39 (24%). A total of 34 (21%) patients died. Of the 285 samples collected for microbiological examinations, 241 (84.5%) blood culture, 39 (13.75%) urine, 2 (0.70%) skin, 1 (0.35%) bone marrow, 1 (0, 35%) sputum, 1 (0.35%) catheter secretion. Of these, 33 (12.0%) have fungi growth, while 91 (32.0%) bacteria. There was no microbial growth in 161 (56.0%). Of the 162 patients with suspected infectious process, 30 (18.51%) were infected by fungal species where 13 (39.39%) Penicillium spp., 12 (36.36%) blood samples were isolated. Most yeast individuals identified within the sensitive range ahead of tested antifungals did not detect any resistance genes. Only two individuals with Candida glabrata have reduced sensitivity to Fluconazole. With these results, it was possible to identify and contextualize several important aspects of these pathogens, such as issues related to public health, clinical, molecular epidemiology and recommended therapy for the most diverse infectious processes caused by these agentspt_BR
dc.languageporpt_BR
dc.publisherUniversidade do Estado do Amazonaspt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectInfecções fúngicaspt_BR
dc.subjectDoenças hematológicaspt_BR
dc.subjectSucetibilidade antifúngica,pt_BR
dc.subjectEpidemiologia molecularpt_BR
dc.titleCaracterização molecular de espécies fúngicas isoladas de processos infecciosos de pacientes da Fundação de Hematologia e Hemoterapia do Amazonaspt_BR
dc.title.alternativeMolecular characterization of fungal species isolated from infectious processes of patients from Fundação de Hematologia e Hemoterapia do Amazonaspt_BR
dc.typeDissertaçãopt_BR
dc.date.accessioned2022-08-11T17:02:32Z-
dc.contributor.advisor-co1Ferreira, William Antunes-
dc.contributor.advisor-co1Latteshttp://lattes.cnpq.br/9487847737983248pt_BR
dc.contributor.advisor1Ferreira, Cristina Motta-
dc.contributor.advisor1Latteshttp://lattes.cnpq.br/7283507436511006pt_BR
dc.contributor.referee1Passos, Leny Nascimento da Motta-
dc.contributor.referee1Latteshttp://lattes.cnpq.br/8194622149198642pt_BR
dc.contributor.referee2Oliveira, Cintia Mara Costa de-
dc.contributor.referee2Latteshttp://lattes.cnpq.br/8188087361251251pt_BR
dc.contributor.referee3Cruz, Katia Santana-
dc.description.resumoA incidência de infecções fúngicas tem aumentado em todo o mundo, especialmente no ambiente hospitalar, representando uma das principais complicações infecciosas em pacientes hospitalizados e contribuindo para uma elevada morbimortalidade. Em particularmente em pacientes com doenças hematológicas, que realizam terapia quimioterápica intensa, o que ocasiona a depleção de seu sistema imune, deixando-os suscetíveis a desenvolver infecções como micoses oportunistas, neutropenia e outros fatores de risco. Os agentes etiológicos mais comuns responsáveis por esses processos infecciosos são Aspergillus spp. 38-80% e Candida spp. 28-58%, sendo relatado resistência frente à antifúngicos amplamente utilizados na terapia. A investigação à nível genético contribui para um melhor entendimento da epidemiologia molecular e mecanismos evolutivos desses patógenos. Assim, este estudo teve como objetivo caracterizar a nível molecular espécies de fungos isolados de processos infecciosos de pacientes atendidos da Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas. Trata-se de um estudo transversal, prospectivo e descritivo. O período de coleta de dados foi de novembro de 2017 a outubro de 2018. Os registros foram obtidos através de prontuário, sistema SoftLab e iDoctor. A identificação das espécies de leveduras e teste de suscetibilidade (Fluconazol, Voriconazol, Caspofungina, Micafungina, Anfotericina B e Flucitosina) foram realizados com o equipamento automatizado Vitek-2 Compact. A identificação das espécies de fungos filamentosos foi realizada com o gene Internal Transcribed Spacer. Ainda no âmbito da epidemiologia molecular, realizou-se a genotipagem pelo método Multi Locus Sequence Typing, para definir os sequence types e ancestral comum dos isolados clínicos e contrução de árvore filogenética. Com as análises iniciais dos resultados obtidos, verificou o total de 162 pacientes, 91 (56,2%) do sexo masculino e 71 (44%) feminino, com média de idade de 32 anos; todos de nacionalidade brasileira, sendo que 150 (92,6%) nasceram no estado do Amazonas; 66 (41%) não estudaram; 110 (68%) não posuem ocupação. Dos pacientes diagnosticados com alguma doença hematológica, a leucecemia Linfoblástica aguda foi a mais frequente com 64 (39%) casos, seguida pela Leucemia Mielóide Aguda com 39 (24%). O total de 34 (21%) dos pacientes evoluíram para óbito. Do total das 285 amostras coletadas para exames microbiológicos, 241 (84,5%) hemocultura 39 (13,75%) urina, 2 (0,70%) pele, 1 (0,35%) medula óssea, 1 (0,35%) escarro, 1 (0,35%) secreção de cateter. Destas, 33 (12,0%) apresentram crescimento de fungos enquanto 91 (32,0%) bactérias. Não houve crescimento microbiano em 161 (56,0%). Dos 162 pacientes com suspeita de processo infeccioso, 30 (18,51%) apresentaram infecção por espécies de fungos onde 13 (39,39%) de espécies de Penicillium spp. foram isoladas de 12 (36,36%) amostras de Hemocultura. A maioria dos isolados leveduriformes apresentaram-se dentro da faixa sensível frente aos antifúngicos testados, não detectando nenhum gene de resistência. Apenas dois isolados de Candida glabrata apresentram sensibilidade reduzida ao Fluconazol. Com esses resultados, foi possível identificar e contextualizar diversos aspectos importantes desses patógenos como as questões relacionadas à saúde pública, à clínica, epidemiologia molecular e à terapêutica recomendada para os mais diversos processos infecciosos causados por esses agentespt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.programPPGH -PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS APLICADAS À HEMATOLOGIApt_BR
dc.relation.references1. Schadewaldt H. First steps of medical mycology in Germany. Mykosen. 1981; 24(11): 654- 667. 2. Gemeinhardt H. 150 years of medical mycology. Zeitschrift für die gesamte Hygiene und ihre Grenzgebiete. 1990; 36(4): 191-194. 3. Espinel-Ingroff A. History of medical mycology in the United States. Clinical Microbiology Reviews. 1996; 9(2): 235-272. 4. Ajello L. Italian contributions to the history of general and medical mycology. Medical Mycology. 1998; 36(1): 1-11. 5. Whittaker RH. New Concepts of Kingdoms of Organisms. Science. 1969; 163: 151-160. 6. Spatafora JW, Aime MC, Grigoriev IV, Martin F, Stajich JE, Blackwell M. The fungal tree of life: From molecular systematics to genome-scale phylogenies. Microbiology Spectrum. 2017; 5(5). 7. Stajich JE. Fungal Genomes and Insights into the Evolution of the Kingdom. Microbiology Spectrum. 2017; 5(4). 8. Sidrim JJC, Rocha MFG. Micologia Médica à Luz de Autores Contemporâneos. 1th ed. Rio de Janeiro: Guanabara Koogan; 2004. 9. Chowdhary A, Perfect J, Hoog GS. Black Molds and Melanized Yeasts Pathogenic to Humans. Cold Spring Harbor Perspectives in Medicine. 2015; 5: a019570. 10. Lacaz CS, Porto E, Martins JEC, Heins-Vaccari EM, Takahashi NM. Tratado de Micologia Médica. 9th ed. São Paulo: Sarvier; 2002. 11. Li J, Vinh DC, Casanova JL, Puel A. Inborn errors of immunity underlying fungal diseases in otherwise healthy individuals. Current Opinion in Microbiology. 2017; 40: 46-57. 67 12. Rocha DFS, Cruz KS, Santos CSS, Menescal LSF, Neto JRS, Pinheiro SB. MLST reveals a clonal population structure for Cryptococcus neoformans molecular type VNI isolates from clinical sources in Amazonas, Northern-Brazil. 2017; 13(6): e0197841. 13. Góralska K, Blaszkowska J, Dzikowiec M. Neuroinfections caused by fungi. Infection. 2018; 46(4): 443-459. 14. Andes DR, Safdar N, Baddley JW, Alexander B, Brumble L, Freifeld A, et al. The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant‐Associated Infection Surveillance Network (TRANSNET). Transplant Infectious Diseases. 2016; 18: 921-931. 15. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Frontiers in Microbiology. 2017; 7: 2173. 16. Canela HMS, Cardoso B, Vitali LH, Coelho HC, Martinez R, Ferreira MEDS. Prevalence, virulence factors and antifungal susceptibility of Candida spp. isolated from bloodstream infections in a tertiary care hospital in Brazil. Mycoses. 2018; 61: 11-21. 17. Antinori S, Milazzo L, Sollima S, Galli M, Corbellino M. Candidemia and invasive candidiasis in adults: A narrative review. European Journal of Internal Medicine. 2016; 34: 21- 28. 18. Mantadakis E, Pana ZD, Zaoutis T. Candidemia in children: Epidemiology, prevention, and Management. Mycoses. 2018; 15. 19. Köhler JR, Hube B, Puccia R, Casadevall A, Perfect JR. Fungi that Infect Humans. Microbiology Spectrum. 2017. 20. Guinea J. Global trends in the distribution of Candida species causing candidemia. Clinical Microbiology and Infection. 2014; 20: 5-10. 21. Pappas PG, Kauffman CA, Andes DR. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015; 62: 150. 22. Brady AC, Wong B, Pfeiffer CD. Utilizing Rapid Diagnostics for Detection of Candida Species. Current Treatment Options in Infectious Diseases. 2015; 7(3): 127-141. 23. Mutschlechner W, Karall D, Hartmann C, Streiter B, Baumgartner-Sigl S, Orth-Höller D, et al. Mammary candidiasis: molecular-based detection of Candida. European Journal of Clinical Microbiology & Infectious Diseases. 2016; 35: 1309-1313. 24. Fang W, Fa Z, Liao W. Epidemiology of Cryptococcus and cryptococcosis in China. Fungal Genetics and Biology. 2015; 78: 7-15. 25. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infectious Disease. 2017; 17(8): 873-881. 68 26. Kwon-Chung KJ, Bennett JE, Wickes BL, Meyer W, Cuomo CA, Wollenburg KR, et al. The Case for Adopting the "Species Complex" Nomenclature for the Etiologic Agents of Cryptococcosis. mSphere. 2017; 2(1): e00357-16. 27. Ellabib MS, Aboshkiwa MA, Husien WM, D'Amicis R, Cogliati M. Isolation, Identification and Molecular Typing of Cryptococcus neoformans from Pigeon Droppings and Other Environmental Sources in Tripoli, Libya. Mycopathologia. 2016; 181(7-8):603-608. 28. Maziarz EK, Perfect JR. Cryptococcosis. Infectious Disease Clinics of North America. 2016; 30(1):179-206. 29. Jarvis JN, Bicanic T, Loyse A. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: Implications for improving outcomes. Clinical Infectious Diseases. 2014; 58(5): 736-745. 30. Esher SK, Zaragoza O, Alspaugh JA. Cryptococcal pathogenic mechanisms: a dangerous trip from the environment to the brain. Memórias do Instituto Oswaldo Cruz. 2018; 113(7): e180057. 31. Chammard TB, Temfack E, Lortholary O, Alanio A. Diagnostic and therapeutic strategies in cryptococcosis: impact on outcome. Memórias do Instituto Oswaldo Cruz. 2018; 113(7): e180050. 32. WHO - World Health Organization. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. 2018. Available from: http:// www.who.int/hiv/pub/guidelines/cryptococcal-disease/en/. 33. Molloy SF, Kanyama C, Heyderman RS, Loyse A, Kouanfack C, Chanda D, et al. Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. The New England Journal of Medicine. 2018; 378:1004-1017. 34. Anvisa. Detecção e Identificação dos Fungos de Importância Médica - Módulo VII. Brasília: 2013. 35. Chowdhary A, Perfect J, Hoog GS. Black Molds and Melanized Yeasts Pathogenic to Humans. Cold Spring Harbor Perspectives in Medicine. 2015; 5: a019570. 36. Levetin E, Horner WE, Scott JA. Taxonomy of Allergenic Fungi. Journal of Allergy and Clinical Immunology: In Practice. 2016; 4(3): 375-385.e1. 37. Dadar M, Tiwari R, Karthik K, Chakraborty S, Shahali Y, Dhama K. Candida albicans - Biology, molecular characterization, pathogenicity, and advances in diagnosis and control - An update. Microbial Pathogenesis. 2018; 117: 128-138. 38. Quinto-Alemany D, Canerina-Amaro A, Hernández-Abad LG, Machín F, Romesberg FE, Gil-Lamaignere C. Yeasts acquire resistance secondary to antifungal drug treatment by adaptive mutagenesis. PLoS One. 2012; 7(7): e42279. 69 39. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—Third Edition, M27-A3. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute; 2008. p. 40. 40. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Fourth Informational Supplement - M27-S4. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute; 2012. p. 32. 41. Koneman EW, Allen SD, Winn WC, Janda WM, Procop GW, Schreckenberger PC, et al. Diagnóstico Microbiológico: Texto e Atlas Colorido. Rio de Janeiro, Brasil: Guanabara Koogan; 2010. 1565 p. 42. Crocker J, Burnett D. The Science of Laboratory Diagnosis. 2 ed. Nova Jersey, EUA: Wiley; 2005. 564 p. 43. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503-35. 44. Pfaller MA, Rex JH, Rinaldi MG. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis. 1997;24(5):776-84. 45. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis. 1997;24(2):235-47. 46. McKeating C, White PL, Posso R, Palmer M, Johnson E, McMullan R. Diagnostic accuracy of fungal PCR and β-D-glucan for detection of candidaemia: a preliminar evaluation. J Clin Pathol. 2017;0:1–5. 47. Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP. Continuous fluorescence monitoring of rapid cycle DNA amplification. 1997. BioTechniques. 2013 Jun;54(6):314-20. 48. Moreira-Oliveira MS, Mikami Y, Miyaji M, Imai T, Schreiber AZ, Moretti ML. Diagnosis of candidemia by polymerase chain reaction and blood culture: prospective study in a high-risk population and identification of variables associated with development of candidemia. Eur J Clin Microbiol Infect Dis. 2005;24(11):721-6. 49. CLSI. Interpretive Criteria for Identification of Bacteria and Fungi by DNA Target Sequencing; Approved Guideline. CLSI document MM18-A, Clinical and Laboratory Standards Institute. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute; 2008. 50. Arbefeville S, Harris A, Ferrieri P. Comparison of sequencing the D2 region of the large subunit ribosomal RNA gene (MicroSEQ®) versus the internal transcribed spacer (ITS) regions using two public databases for identification of common and uncommon clinically relevant fungal species. Journal of Microbiological Methods. 2017;140:40-46. 70 51. Wengenack NL, Binnicker MJ. Fungal molecular diagnostics. Clin Chest Med. 2009;30(2):391-408, viii. 52. Meiklejohn KA, Damaso N, Robertson JM. Assessment of BOLD and GenBank – Their accuracy and reliability for the identification of biological materials. PLos One. 2019: 14(6): e0217084. 53. Choo KH, Lee HJ, Knight NJ, Holmes AR, Cannon RD. Multilocus sequence typing (MLST) analysis of Candida albicans isolates colonizing acrylic dentures before and after denture replacement. Medical Mycology. 2016; 1–7. 54. Colombo AL, Guimarães T, Camargo LF, Richtmann R, Queiroz-Telles F, Salles MJ, et al. Brazilian guidelines for the management of candidiasis - a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical. Braz J Infect Dis. 2013;17(3): 283-312. 55. Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN, Cortes J, Zurita J, et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One. 2013;8(3):e59373. 56. Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW. Manual Of Clinical Microbiology. 10, editor. Washington, DC: American Society For Microbiology; 2011. 57. Vandeputte P, Ferrari S, Coste AT. Antifungal resistance and new strategies to control fungal infections. Int J Microbiol. 2012;2012:713687. 58. Carvalho VO. Identificação e análise de mutações no gene ERG11 de isolados de Candida susceptíveis e resistentes ao fluconazol [Master's Program]. Brasil: Universidade de São Paulo; 2010. 59. Cornely OA, Flörl CL, Lagrou K, Arsenijevic VA, Hoenigl M. Improving outcome of fungal diseases - Guiding experts and patients towards excellence. Mycoses. 2017; 1-6. 60. Junior MC, Silva HM, Arantes AM, Costa CR, Ataides FS, Silva TC, et al. Invasive fungal infection in patients with hematologic disorders in a Brazilian tertiary care hospital. Revista da Sociedade Brasileira de Medicina Tropical. 2017; 50(1): 80-85. 61. CDC (Centers for Disease Control and Prevention) [Internet]. Estados Unidos. 2014 [citado em 2018 Jul 12]. Disponível em: https://www.cdc.gov/fungal/global/index.html. 62. M Dong, X Li, J Liu, Z Song, H Zhao, S Wei, et. al. Successful surgical management of invasive pulmonary fungal infection in patients with leucemia. Infection and Drug Resistance. 2019:12 1675-1681. 63. Junior MC, Silva HM, Arantes AM, Costa CR, Ataides FS, Silva TC, et al. Invasive fungal infection in patients with hematologic disorders in a Brazilian tertiary care hospital. Revista da Sociedade Brasileira de Medicina Tropical. 2017; 50(1): 80-85. 64. Cheikh JE, Ceballos P, Dalle JH, Ducastelle-Leprêtre S, Dulon E, Herbrecht R. Micafungin prophylaxis in routine medical practice in adult and pediatric patients with hematological 71 malignancy: A prospective, observational study in France. Diagnostic Microbiology and Infectious Disease. 2019; 94(3):268-273. 65. Borges DP, Santos AWA, Magalhaes SMM, Sidrim JJ, Rocha MFG, Cordeiro RA, Brilhante RSN, Bandeira SP, Junior JTV, Pinheiro RF. Fusarium solani infection as an initial manifestation of AML transformation in myelodysplastic syndrome: A case report. Journal de Mycologie Médicale. 2018. 66. Foster CE, Edwards MS, Brackett J, Schady DA, Healy CM, Baker CJ. Trichosporonosis in Pediatric Patients With a Hematologic Disorder. Journal of the Pediatric Infectious Diseases Society. 2017;1-6. 67. JS, Hermes DM, Pasqualotto AC. Galactomannan use in clinical practice: providingfree testing is not the answer. Braz J Infect Dis. 2017. 68. Nucci F, Nouér SA, Capone D, Nucci M. Invasive Mold Disease in Hematologic Patients: Comparison between Fusariosis and Aspergillosis. 2018;24(10): 1105.e1-1105.e4. 69. Ferreira CM, Andrade DR, Souza VS, Ferreira GMA, Ferreira WA. Effectiveness of Modified Sabouraud Medium in Relation to the Bacterial Growth. SOJ Microbiology & Infectious Diseases. 2016; 4(2): 1-3. 70. Rocha DFS. G [Internet]. Epidemiologia molecular dos agentes da Criptococose e perfil de susceptibilidade antifúngica de isolados clínicos obtidos em um centro de referência no Amazonas. Universidade do Estado do Amazonas (UEA), Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (FMT-HVD); 2016. 71. Jimenez KL. Características moleculares e perfil de sensibilidade a antifúngicos de leveduras do gênero Candida spp isoladas de paciente com candidíase vulvovaginal. Universidade do Estado do Amazonas (UEA), Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (FMT-HVD); 2015. 72. Vitek-2 Compact [Internet]. Estados Unidos. 2014 [citado em 2018 Jul 17]. Disponível em: https://store.pda.org/tableofcontents/ermm_v2_ch01.pdf 73. White TJ, Bruns T, Lee S, Taylor J. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: M.A. Innis, D.H. Gelfand, J.J. Sninsky & T.J. White (eds.). PCR Protocols: A Guide to Methods and Applications. 1990; 315-322. 74. Meyer W, Aanensen DM, Boekhout T, Cogliati M, Diaz MR, Esposto MC. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol. 2009;47(6):561-570. 75. Bougnoux ME, Morand S, d’Enfert C. Usefulness of Multilocus Sequence Typing for Characterization of Clinical Isolates of Candida albicans. Journal of Clinical Microbiology. 2002; 40(4): 1290-1297. 76. Dodgson AR, Pujol C, Denning DW, Soll DR, Fox AJ. Multilocus Sequence Typing of Candida glabrata Reveals Geographically Enriched Clades. Journal of Clinical Microbiology. 2003; 41(12): 5709-5717. 72 77. Tavanti A, Davidson AD, Johnson EM, Maiden MCJ, Shaw DJ, Gow NAR., et. al. Multilocus Sequence Typing for Differentiation of Strains of Candida tropicalis. Journal of Clinical Microbiology. 2005; 43(11): 5593-5600. 78. Saitou N, Nei M. The neighbor-joining method: A new method for reconstructing phylogenetic trees. Molecular Biology and Evolution. 1987; 4: 406-425pt_BR
dc.publisher.initialsUEApt_BR
Aparece nas coleções:DISSERTAÇÃO - PPCAH Programa de Pós-Graduação em Ciências Aplicadas à Hematologia



Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.